Aeterna falls on suspending US sales of growth hormone deficiency drug

COSCIENS Biopharma

05/04/2023 15:53

** U.S.-listed shares  AEZS.O  of Canadian biopharma Aeterna
Zentaris Inc fall ~6% to $2.41
    ** Company says U.S. sales of its drug to treat adult growth
hormone deficiency will be discontinued temporarily
    ** Sales of the drug, Macrilen, will be discontinued
effective May 23 until relaunch with an alternate
commercialization partner, says Aeterna
    ** Company says decision comes after Novo Nordisk  NOVOb.CO 
unit ended licensing deal for Macrilen in North America last
year
    ** Including session's moves, Aeterna's U.S.-listed shares
down ~24% this year

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com))